Lancet Oncology

Published by: Elsevier Science, Inc.  

People

  1. Bodei
    Bodei
  2. Gonen
    Gonen
  3. Pandit-Taskar
    Pandit-Taskar
  4. Russo
    Russo
  5. Arcila
    Arcila
  6. Balachandran
    Balachandran
  7. Carrasquillo
    Carrasquillo
  8. Cheung
    Cheung
  9. Coleman
    Coleman
  10. D'Angelica
    D'Angelica

Groups

  1. Sloan Kettering Institute Postdocs (12)
  2. Radiology, Department of (6)
  3. Biostatistics Service (5)
  4. Epidemiology and Biostatistics (5)
  5. GSK Faculty (5)
  6. Surgery (5)
  7. Department of Medicine (4)
  8. Molecular Imaging and Therapy Service (4)
  9. Solid Tumor Oncology Division (4)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
Search Within
  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (8)
  2. Review (2)
  3. Correspondence (1)
  4. Editorial (1)
Groups
  1. Sloan Kettering Institute Postdocs (12)
  2. Radiology, Department of (6)
  3. Biostatistics Service (5)
  4. Epidemiology and Biostatistics (5)
  5. GSK Faculty (5)
  6. Surgery (5)

More Groups

People
  1. Lisa Bodei (2)
  2. Mithat Gonen (2)
  3. Neeta Pandit-Taskar (2)
  4. Paul Russo (2)
  5. Steven Larson (2)
  6. Sujata Patil (2)

More People

Years
  1. 2022 (2)
  2. 2021 (3)
  3. 2020 (2)
  4. 2018 (2)
  5. 2016 (2)
  6. 2007 (1)
Publishers
  1. Elsevier Science, Inc. (12)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: A retrospective study and meta-analysis
    Journal Article

    Ecker, B. L.; Lee, J.; Saadat, L. V.; Aparicio, T.; Buisman, F. E.; Balachandran, V. P.; Drebin, J. A.; Hasegawa, K.; Jarnagin, W. R.; Kemeny, N. E.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Combination regimens in EGFR-mutated lung cancer: Can we get ORIENT-ed?
    Editorial

    Elkrief, A.; Yu, H.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
    Journal Article

    Strosberg, J. R.; Caplin, M. E.; Kunz, P. L.; Ruszniewski, P. B.; Bodei, L.; Hendifar, A.; Mittra, E.; Wolin, E. M.; Yao, J. C.; Pavel, M. E.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Interpreting the RAPIDO trial: Factors to consider
    Correspondence

    Yuval, J. B.; Patil, S.; Garcia-Aguilar, J.
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: The Lucerne toolbox
    Review

    Dubsky, P.; Pinker, K.; Cardoso, F.; Montagna, G.; Ritter, M.; Denkert, C.; Rubio, I. T.; de Azambuja, E.; Curigliano, G.; Gentilini, O.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
    Review

    Bodei, L.; Schöder, H.; Baum, R. P.; Herrmann, K.; Strosberg, J.; Caplin, M.; Öberg, K.; Modlin, I. M.
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: A cohort study
    Journal Article

    Sanchez, A.; Furberg, H.; Kuo, F.; Vuong, L.; Ged, Y.; Patil, S.; Ostrovnaya, I.; Petruzella, S.; Reising, A.; Patel, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Convection-enhanced delivery for diffuse intrinsic pontine glioma: A single-centre, dose-escalation, phase 1 trial
    Journal Article

    Souweidane, M. M.; Kramer, K.; Pandit-Taskar, N.; Zhou, Z.; Haque, S.; Zanzonico, P.; Carrasquillo, J. A.; Lyashchenko, S. K.; Thakur, S. B.; Donzelli, M.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): An international, randomised, phase 3, non-inferiority trial
    Journal Article

    Iveson, T. J.; Kerr, R. S.; Saunders, M. P.; Cassidy, J.; Hollander, N. H.; Tabernero, J.; Haydon, A.; Glimelius, B.; Harkin, A.; Allan, K.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Journal Article

    Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save

    • Lancet Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 1470-2045 Elsevier B.V.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 0094-0143 Unknown
    Lancet Oncology 0732-183X Unknown
    Lancet Oncology 1089-9472 Unknown
    Lancet Oncology 0938-7994 Unknown
    Lancet Oncology 2314-6133 Unknown
    Lancet Oncology 2152-2650 Unknown
    Lancet Oncology 1471-2407 Unknown
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Unknown
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 14702045 Elsevier Inc.
    Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Science, Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Unknown
    The Lancet Oncology 1474-5488 Elsevier Inc.
    The Lancet Oncology 14702045 Elsevier Inc.
    The Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Inc.
    The Lancet. Oncology 1474-5488 Unknown
    The Lancet. Oncology 14745488 Unknown